WO2021243203A1 - Bilayer of retinal pigmented epithelium and photoreceptors and use thereof - Google Patents

Bilayer of retinal pigmented epithelium and photoreceptors and use thereof Download PDF

Info

Publication number
WO2021243203A1
WO2021243203A1 PCT/US2021/034851 US2021034851W WO2021243203A1 WO 2021243203 A1 WO2021243203 A1 WO 2021243203A1 US 2021034851 W US2021034851 W US 2021034851W WO 2021243203 A1 WO2021243203 A1 WO 2021243203A1
Authority
WO
WIPO (PCT)
Prior art keywords
rpe
cells
prp
tissue
tissue culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/034851
Other languages
English (en)
French (fr)
Inventor
Andrew DIAS
Erich BERNDT
Lucas Chase
Juan AMARAL
Arvydas Maminishkis
Kapil BHARTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Cellular Dynamics Inc
US Department of Health and Human Services
Original Assignee
Fujifilm Cellular Dynamics Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL298254A priority Critical patent/IL298254A/en
Priority to JP2022573582A priority patent/JP2023536210A/ja
Priority to CN202180039069.3A priority patent/CN116323677A/zh
Priority to KR1020227046209A priority patent/KR20230017876A/ko
Priority to US18/000,008 priority patent/US20230212509A1/en
Priority to AU2021280332A priority patent/AU2021280332A1/en
Priority to EP21737240.8A priority patent/EP4157865A1/en
Priority to MX2022015002A priority patent/MX2022015002A/es
Application filed by Fujifilm Cellular Dynamics Inc, US Department of Health and Human Services filed Critical Fujifilm Cellular Dynamics Inc
Priority to PH1/2022/553083A priority patent/PH12022553083A1/en
Priority to CA3180561A priority patent/CA3180561A1/en
Priority to BR112022024064A priority patent/BR112022024064A2/pt
Publication of WO2021243203A1 publication Critical patent/WO2021243203A1/en
Anticipated expiration legal-status Critical
Priority to US19/418,651 priority patent/US20260103678A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3869—Epithelial tissues other than skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0056—Xeno-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/083—Coculture with; Conditioned medium produced by cells of the nervous system sensory transducers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Definitions

  • Age-related macular degeneration is a debilitating condition affecting 11 million people in the United States and 170 million worldwide as of 2016, and global prevalence is expected to reach 196 million in 2020 (Pennington and DeAngelis, 2016; Wong et al., 2014). Its cause is presumed dysfunction in the retinal pigmented epithelium (RPE), which leads to death and dysfunction of photoreceptors (Bhutto and Lutty, 2012).
  • RPE retinal pigmented epithelium
  • Cell therapies using RPE may be effective for treating AMD, myopic macular degeneration, or rarer forms of inherited macular degeneration, and there are currently several ongoing and planned stem cell- based clinical trials to restore visual function (Oner, 2018).
  • the present disclosure provides a tissue replacement implant comprising photoreceptor precursor cells (PRP) and/or photoreceptor cells (PR) in combination with retinal pigment epithelium cells (RPE) on a biodegradable scaffold.
  • PRP photoreceptor precursor cells
  • PR photoreceptor cells
  • RPE retinal pigment epithelium cells
  • the implant is defined, xeno-free, and feeder-free.
  • a further embodiment provides a pharmaceutical composition
  • the tissue replacement implant of the present embodiments or aspects thereof e.g., a tissue replacement implant comprising photoreceptor precursor cells (PRP) and/or photoreceptor cells (PR) in combination with retinal pigment epithelium cells (RPE) on a biodegradable scaffold.
  • the composition further comprises sodium hyaluronate.
  • the hyaluronate is present at a concentration of less than about 0.5%, such as 0.4%, 0.3%, or 0.2%.
  • the composition further comprises sodium bicarbonate, calcium chloride, potassium chloride, potassium phosphate monobasic, magnesium chloride, magnesium sulfate, sodium chloride, and/or sodium phosphate dibasic.
  • the PR/PRP are seeded at a concentration of about 100,000 cells/cm 2 to about 10 million cells/cm 2 , such as about 200,000 cells/cm 2 , 300,000 cells/cm 2 , 400,000 cells/cm 2 , 500,000 cells/cm 2 , 600,000 cells/cm 2 , 700,000 cells/cm 2 , 800,000 cells/cm 2 , or 900,000 cells/cm 2 .
  • the PR/PRP are seeded at a concentration of about 3 million cells/cm 2 to about 5 million cells/cm 2 , such as about 4 million cells/cm 2 .
  • the biodegradable scaffold is placed in a multi-well support with a tissue culture insert.
  • the first tissue culture medium is added to a lower compartment of the multi-well support with a tissue culture insert.
  • the second tissue culture medium is added to an upper compartment of the multi-well support with a tissue culture insert.
  • the first tissue culture medium comprises taurine and hydrocortisone.
  • the first tissue culture media further comprises triiodothyronine.
  • the first tissue culture medium is defined media or serum-free media.
  • the first tissue culture medium comprises serum replacement.
  • FIGS. 4A-4F RPE/PRP ratio quantification 7 days after 4e6 PRP are plated on a confluent monolayer of RPE.
  • RPE is indicated by TYRP1 and PRP is indicated by AIPL1.
  • FIG. 4A Flow cytometry plot of iPRP control
  • FIG. 4B Flow cytometry plot of iRPE control
  • FIG. 4C Flow cytometry plot of RPE cultured on a Snapwell in mono-culture
  • FIG. 4D Flow cytometry plot of PRP cultured on top of polarized RPE for seven days in co-culture.
  • the RPE are first cultured on a surface.
  • the RPE may be cultured to generate polarized RPE that are positive for late polarization marker Bestrophin.
  • the RPE may be derived from hiPSCs, such as by the method disclosed in PCT/US2016/050543 and PCT/US2016/050554, both incorporated herein by reference in their entirety, or may be embryonic or fetal RPE.
  • the PR PRPs may also be derived from hiPSCs, such as by the method disclosed in PCT/US2019/028557, incorporated herein by references in its entirety, or ES cells.
  • Super donors are referred to herein as individuals that are homozygous for certain MHC class I and II genes. These homozygous individuals can serve as super donors and their cells, including tissues and other materials comprising their cells, can be transplanted in individuals that are either homozygous or heterozygous for that haplotype.
  • the super donor can be homozygous for the HLA- A, HLA-B, HLA-C, HLA-DR, HLA-DP or HLA-DQ locus/loci alleles, respectively.
  • RPCs spinal progenitor cells
  • neural retina cells such as rods, cones, photoreceptor precursor cells, as well as cells which can differentiate into RPE.
  • photoreceptor precursor cells or “PRP” refer to cells differentiated from embryonic stem cells or induced pluripotent stem cells which can differentiate into photoreceptor cells that expresses the cell marker rhodopsin or any of the three cone opsins.
  • the photoreceptors may be rod and/or cone photoreceptors.
  • biodegradable refers to a material that provides initial structural support to delivered cells, but degrades over time into products that are not toxic to the transplant host and do not contribute to donor site morbidity.
  • Reprogramming may further comprise contacting the cells with one or more signaling receptors including glycogen synthase kinase 3 (GSK-3) inhibitor, a mitogen-activated protein kinase kinase (MEK) inhibitor, a transforming growth factor beta (TGF-b) receptor inhibitor or signaling inhibitor, leukemia inhibitory factor (LIF), a p53 inhibitor, an NF-kappa B inhibitor, or a combination thereof.
  • GSK-3 glycogen synthase kinase 3
  • MEK mitogen-activated protein kinase kinase
  • TGF-b transforming growth factor beta
  • LIF leukemia inhibitory factor
  • p53 inhibitor a p53 inhibitor
  • NF-kappa B inhibitor a combination thereof.
  • Those regulators may include small molecules, inhibitory nucleotides, expression cassettes, or protein factors. It is anticipated that virtually any iPS cells or cell lines may be used.
  • pluripotent cells may be cultured on fibroblast feeder cells or a medium that has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state.
  • the cell is cultured in the co-presence of mouse embryonic fibroblasts treated with radiation or an antibiotic to terminate the cell division, as feeder cells.
  • pluripotent cells may be cultured and maintained in an essentially undifferentiated state using a defined, feeder-independent culture system, such as a TESRTM medium (Ludwig et al, 2006a; Ludwig et al. , 2006b) or E8TM medium (Chen et al. , 2011).
  • Mature retinal pigment epithelium expresses markers such as cellular retinaldehyde-binding protein (CRALBP), RPE65, best vitelliform macular dystrophy gene (VMD2), and pigment epithelium derived factor (PEDF).
  • CRALBP cellular retinaldehyde-binding protein
  • RPE65 RPE65
  • VMD2 best vitelliform macular dystrophy gene
  • PEDF pigment epithelium derived factor
  • Malfunction of the retinal pigment epithelium is associated with a number of vision- altering conditions, such as retinal pigment epithelium detachment, dysplasia, atrophy, retinopathy, retinitis pigmentosa, macular dystrophy, or degeneration, including age-related macular degeneration.
  • the retinal lineage cells can then be cultured in Retinal Differentiation Medium (RDM) for further differentiation.
  • RDM comprises a WNT pathway inhibitor, a BMP pathway inhibitor, a TGF pathway inhibitor and a MEK inhibitor.
  • the RDM comprises a WNT pathway inhibitor, such as CKI-7, a BMP pathway inhibitor, such as LDN193189, a TGF pathway inhibitor, such as SB431542, and a MEK inhibitor, such as PD0325901.
  • the RDM can comprise a WNT pathway inhibitor, a BMP pathway inhibitor, a TGF pathway inhibitor and a bFGF inhibitor.
  • the differentiated retinal cells can be even further differentiated by culturing the cells in Retinal Medium (RM).
  • the Retinal Medium comprises Activin A and can additionally comprise Nicotinamide.
  • the RM can comprise about 50 to about 200 ng/mL, such as about 100 ng/mL, of ACTIVIN A, and about 1 mM to about 50 mM, such as about 10 mM, of nicotinamide.
  • the RPE-MM can comprise MEM Alpha, N-2 supplement, MEM non-essential amino acids (NEAA), and sodium pyruvate, and fetal bovine serum (or KnockOutTM Serum Replacement) (e.g., about 0.5% to about 10%, such as about 1% to about 5%).
  • the medium can be changed every other day with room temperature RPE-MM.
  • the cells are generally cultured in RPE-MM for about 5 to about 10 days, such as about 5 days.
  • the cells can then be dissociated, such as with a cell dissociation enzyme, reseeded, and cultured for an additional period of time, such as an additional about 5 to about 30 days, such as about 15 to 20 days, for further differentiation into RPE cells.
  • the RPE-MM does not include a WNT pathway inhibitor.
  • RPE cells can be cryopreserved at this stage.
  • methods are provided for producing photoreceptors from an essentially single cell suspension of PSCs such as human iPSCs.
  • the PSCs are cultured to pre-confluence.
  • the PSCs are dissociated by incubation with a cell dissociation solution or enzyme, such as exemplified by Versene, Trypsin, ACCUTASETM or TRYPLETM.
  • PSCs can also be dissociated into an essentially single cell suspension by pipetting.
  • Blebbistatin e.g., about 2.5 mM
  • a ROCK inhibitor instead of Blebbistatin may alternatively be used to increase PSC survival after dissociation into single cells.
  • the cells are generally seeded in an appropriate culture vessel, such as a tissue culture plate, such as a flask, multi layer flask, 6-well, 12-well, 24-well, 96- well or 10 cm plate.
  • a culture vessel used for culturing the cell(s) can include, but is particularly not limited to: flask, flask for tissue culture, dish, Petri dish, dish for tissue culture, multi dish, micro plate, micro-well plate, multi plate, multi well plate, micro slide, chamber slide, tube, tray, CELLSTACK® Chambers, culture bag, and roller bottle, as long as it is capable of culturing the stem cells therein.
  • the total protein concentration in the matrix composition may be about 1 ng/mL to about 1 mg/mL. In some preferred embodiments, the total protein concentration in the matrix composition is about 1 pg/mL to about 300 pg/mL. In more preferred embodiments, the total protein concentration in the matrix composition is about 5 pg/mL to about 200 pg/mL.
  • a WNT inhibitor (also referred to as a WNT pathway inhibitor) herein refers to WNT inhibitors in general.
  • a WNT inhibitor refers to any inhibitor of a member of the WNT family proteins including Wntl, Wnt2, Wnt2b, Wnt3, Wnt4, Wnt5A, Wnt6, Wnt7A, Wnt7B, Wnt8A, Wnt9A, WntlOa, Wntll, and Wntl6.
  • Certain embodiments of the present methods concern a WNT inhibitor in the differentiation medium.
  • TGF Transforming growth factor beta
  • TGF-b is a secreted protein that controls proliferation, cellular differentiation, and other functions in most cells. It is a type of cytokine which plays a role in immunity, cancer, bronchial asthma, lung fibrosis, heart disease, diabetes, and multiple sclerosis. TGF-b exists in at least three isoforms called TGF-bI, TGF- b2 and TGF ⁇ 3. The TGF-b family is part of a superfamily of proteins known as the transforming growth factor beta superfamily, which includes inhibins, activin, anti-miillerian hormone, bone morphogenetic protein, decapentaplegic and Vg-1.
  • bFGF inhibitors herein refer to bFGF inhibitors in general.
  • bFGF inhibitors include, but are not limited to N-[2-[[4-(Diethylamino)butyl]amino-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(l,l-dimethylethyl)urea (PD173074), 2-(2- Amino-3-methoxyphenyl)-4H-l-benzopyran-4-one (PD 98059), l-tert-Butyl-3-[6-(2,6- dichlorophenyl)-2-[[4-(diethylamino)butyl]amino]pyrido[2,3-d]pyrimidin-7-yl]urea (PD161570), 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)e
  • the photoreceptors to layer on top of the RPE may be immature photoreceptors that can be fated to become either rods or cones. Specifically, the photoreceptors may be derived from the hybrid differentiation method described herein.
  • the photoreceptors may be directly seeded onto the RPE from culture or cryopreservation, or they may be re-plated and cultured prior to seeding on the RPE.
  • the photoreceptors may be seeded on the RPE and then cultured for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more days to allow for attachment and generation of the distinct bilayer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
PCT/US2021/034851 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof Ceased WO2021243203A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP21737240.8A EP4157865A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
CN202180039069.3A CN116323677A (zh) 2020-05-29 2021-05-28 视网膜色素上皮和光感受器双层及其用途
KR1020227046209A KR20230017876A (ko) 2020-05-29 2021-05-28 망막 색소 상피 및 광수용체의 이중층 및 이의 용도
US18/000,008 US20230212509A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
AU2021280332A AU2021280332A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
MX2022015002A MX2022015002A (es) 2020-05-29 2021-05-28 Bicapa del epitelio pigmentario de la retina y fotorreceptores y uso de los mismos.
PH1/2022/553083A PH12022553083A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
IL298254A IL298254A (en) 2020-05-29 2021-05-28 Double layer of retinal pigment epithelium and photoreceptors and their uses
JP2022573582A JP2023536210A (ja) 2020-05-29 2021-05-28 網膜色素上皮及び光受容体の二重層、並びにその使用
CA3180561A CA3180561A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
BR112022024064A BR112022024064A2 (pt) 2020-05-29 2021-05-28 Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos
US19/418,651 US20260103678A1 (en) 2020-05-29 2025-12-12 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032346P 2020-05-29 2020-05-29
US63/032,346 2020-05-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US18/000,008 A-371-Of-International US20230212509A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
US19/418,651 Continuation US20260103678A1 (en) 2020-05-29 2025-12-12 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof

Publications (1)

Publication Number Publication Date
WO2021243203A1 true WO2021243203A1 (en) 2021-12-02

Family

ID=76744923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/034851 Ceased WO2021243203A1 (en) 2020-05-29 2021-05-28 Bilayer of retinal pigmented epithelium and photoreceptors and use thereof

Country Status (12)

Country Link
US (2) US20230212509A1 (https=)
EP (1) EP4157865A1 (https=)
JP (1) JP2023536210A (https=)
KR (1) KR20230017876A (https=)
CN (1) CN116323677A (https=)
AU (1) AU2021280332A1 (https=)
BR (1) BR112022024064A2 (https=)
CA (1) CA3180561A1 (https=)
IL (1) IL298254A (https=)
MX (1) MX2022015002A (https=)
PH (1) PH12022553083A1 (https=)
WO (1) WO2021243203A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039688A3 (en) * 2022-08-15 2024-04-04 Cellino Biotech, Inc. Systems and methods for cell manufacturing
WO2024157203A1 (en) * 2023-01-27 2024-08-02 Alcon Inc. Induced pluripotent stem cell (ipsc) derived multi-ribbon biodegradable gel for outer retinal replacement
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions
WO2026006245A1 (en) 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250075772A (ko) * 2023-11-21 2025-05-29 싱귤래리티 바이오텍(주) 망막 오가노이드로부터 망막전구세포를 제조하는 방법 및 이의 용도
CN119950819B (zh) * 2025-02-11 2025-10-21 中国人民解放军陆军第九五八医院 用于治疗视网膜色素变性的类器官双层三维组织植片及其制备方法

Citations (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
WO1994009699A1 (en) 1992-10-30 1994-05-11 British Technology Group Limited Investigation of a body
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1995006128A2 (en) 1993-08-25 1995-03-02 Dekalb Genetics Corporation Fertile, transgenic maize plants and methods for their production
US5538880A (en) 1990-01-22 1996-07-23 Dekalb Genetics Corporation Method for preparing fertile transgenic corn plants
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5556954A (en) 1992-02-13 1996-09-17 Beth Israel Hospital Boston Association Hematopoietic stem cell specific gene expression
US5563055A (en) 1992-07-27 1996-10-08 Pioneer Hi-Bred International, Inc. Method of Agrobacterium-mediated transformation of cultured soybean cells
US5580859A (en) 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US5789215A (en) 1991-08-20 1998-08-04 Genpharm International Gene targeting in animal cells using isogenic DNA constructs
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5925565A (en) 1994-07-05 1999-07-20 Institut National De La Sante Et De La Recherche Medicale Internal ribosome entry site, vector containing it and therapeutic use
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5935819A (en) 1992-08-27 1999-08-10 Eichner; Wolfram Process for producing a pharmaceutical preparation of PDGF-AB
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6103470A (en) 1995-06-07 2000-08-15 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US20020055144A1 (en) 1996-04-11 2002-05-09 Human Genome Sciences, Inc. Human hematopoietic-specific protein
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US6833269B2 (en) 2000-05-17 2004-12-21 Geron Corporation Making neural cells for human therapy or drug screening from human embryonic stem cells
WO2007069666A1 (ja) 2005-12-13 2007-06-21 Kyoto University 核初期化因子
US7442548B2 (en) 2004-09-08 2008-10-28 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid
US20090148425A1 (en) 2005-10-28 2009-06-11 Tsukasa Ohmori Therapeutic method for blood coagulation disorder
US20090246875A1 (en) 2007-12-10 2009-10-01 Kyoto University Efficient method for nuclear reprogramming
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
US20100003757A1 (en) 2008-06-04 2010-01-07 Amanda Mack Methods for the production of ips cells using non-viral approach
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US20100210014A1 (en) 2005-12-13 2010-08-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US7989425B2 (en) 2002-09-27 2011-08-02 Genexine Inc. Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US20120196360A1 (en) 2009-08-07 2012-08-02 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US8268620B2 (en) 2008-10-24 2012-09-18 Wisconsin Alumni Research Foundation OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells
US8278620B2 (en) 2010-05-03 2012-10-02 Thermo Finnigan Llc Methods for calibration of usable fragmentation energy in mass spectrometry
US20120276636A1 (en) 2010-01-22 2012-11-01 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
WO2012149484A2 (en) 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
US8741648B2 (en) 2009-06-05 2014-06-03 Cellular Dynamics International, Inc. Reprogramming T cells and hematopoietic cells
WO2014121077A2 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
US20160331867A1 (en) * 2015-05-13 2016-11-17 Taipei Veterans General Hospital Multilayered retinal cell implant
US20170226459A1 (en) * 2016-02-05 2017-08-10 Wisconsin Alumni Research Foundation Photoreceptor scaffold for in vitro modeling and transplantation therapy
US20190290701A1 (en) * 2013-03-15 2019-09-26 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985209B2 (ja) * 2011-11-25 2016-09-06 住友化学株式会社 眼杯様構造体の製造方法
CN106955191B (zh) * 2017-03-15 2023-09-19 中山大学中山眼科中心 一种组织工程视网膜膜片玻璃体腔内推注器
CA3074426A1 (en) * 2017-09-08 2019-03-14 Sumitomo Dainippon Pharma Co., Ltd. Cell aggregate including retinal tissue and production method therefor
SG11202104401RA (en) * 2018-11-19 2021-05-28 The United States Of America As Represented By The Secretary Biodegradable tissue replacement implant and its use

Patent Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202B1 (https=) 1985-03-28 1990-11-27 Cetus Corp
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5580859A (en) 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5464765A (en) 1989-06-21 1995-11-07 Zeneca Limited Transformation of plant cells
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5538877A (en) 1990-01-22 1996-07-23 Dekalb Genetics Corporation Method for preparing fertile transgenic corn plants
US5538880A (en) 1990-01-22 1996-07-23 Dekalb Genetics Corporation Method for preparing fertile transgenic corn plants
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5789215A (en) 1991-08-20 1998-08-04 Genpharm International Gene targeting in animal cells using isogenic DNA constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5556954A (en) 1992-02-13 1996-09-17 Beth Israel Hospital Boston Association Hematopoietic stem cell specific gene expression
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5563055A (en) 1992-07-27 1996-10-08 Pioneer Hi-Bred International, Inc. Method of Agrobacterium-mediated transformation of cultured soybean cells
US5935819A (en) 1992-08-27 1999-08-10 Eichner; Wolfram Process for producing a pharmaceutical preparation of PDGF-AB
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
WO1994009699A1 (en) 1992-10-30 1994-05-11 British Technology Group Limited Investigation of a body
WO1995006128A2 (en) 1993-08-25 1995-03-02 Dekalb Genetics Corporation Fertile, transgenic maize plants and methods for their production
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5925565A (en) 1994-07-05 1999-07-20 Institut National De La Sante Et De La Recherche Medicale Internal ribosome entry site, vector containing it and therapeutic use
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6200806B1 (en) 1995-01-20 2001-03-13 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US7029913B2 (en) 1995-01-20 2006-04-18 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6103470A (en) 1995-06-07 2000-08-15 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US20020055144A1 (en) 1996-04-11 2002-05-09 Human Genome Sciences, Inc. Human hematopoietic-specific protein
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US20020076747A1 (en) 1997-01-10 2002-06-20 Paul J. Price Method for expanding embryonic stem cells in serum-free culture
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6833269B2 (en) 2000-05-17 2004-12-21 Geron Corporation Making neural cells for human therapy or drug screening from human embryonic stem cells
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US7989425B2 (en) 2002-09-27 2011-08-02 Genexine Inc. Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US8071369B2 (en) 2003-11-26 2011-12-06 Whitehead Institute For Biomedical Research Compositions for reprogramming somatic cells
US7442548B2 (en) 2004-09-08 2008-10-28 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid
US20090148425A1 (en) 2005-10-28 2009-06-11 Tsukasa Ohmori Therapeutic method for blood coagulation disorder
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US20100210014A1 (en) 2005-12-13 2010-08-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
WO2007069666A1 (ja) 2005-12-13 2007-06-21 Kyoto University 核初期化因子
US8058065B2 (en) 2005-12-13 2011-11-15 Kyoto University Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells
US20090246875A1 (en) 2007-12-10 2009-10-01 Kyoto University Efficient method for nuclear reprogramming
US20100003757A1 (en) 2008-06-04 2010-01-07 Amanda Mack Methods for the production of ips cells using non-viral approach
US8546140B2 (en) 2008-06-04 2013-10-01 Cellular Dynamics International, Inc. Methods for the production of iPS cells using non-viral approach
US8268620B2 (en) 2008-10-24 2012-09-18 Wisconsin Alumni Research Foundation OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells
US8741648B2 (en) 2009-06-05 2014-06-03 Cellular Dynamics International, Inc. Reprogramming T cells and hematopoietic cells
US20120196360A1 (en) 2009-08-07 2012-08-02 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US20120276636A1 (en) 2010-01-22 2012-11-01 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
US8278620B2 (en) 2010-05-03 2012-10-02 Thermo Finnigan Llc Methods for calibration of usable fragmentation energy in mass spectrometry
WO2012149484A2 (en) 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
WO2014121077A2 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
US20190290701A1 (en) * 2013-03-15 2019-09-26 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160331867A1 (en) * 2015-05-13 2016-11-17 Taipei Veterans General Hospital Multilayered retinal cell implant
US20170226459A1 (en) * 2016-02-05 2017-08-10 Wisconsin Alumni Research Foundation Photoreceptor scaffold for in vitro modeling and transplantation therapy

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
ALEXANDER ET AL., PROC. NAT. ACAD. SCI. USA, vol. 85, 1988, pages 5092 - 5096
BARNEA-CRAMER ET AL., SCI REP., vol. 6, 2016, pages 29784
BHUTTOLUTTY, MOL ASPECTS MED, vol. 33, no. 4, 2012, pages 295 - 317
CHEN YU ET AL: "Photoreceptor degeneration in microphthalmia (Mitf) mice: Partial rescue by pigment epithelium-derived factor", DISEASE MODELS & MECHANISMS, vol. 12, no. 1, 1 January 2019 (2019-01-01), GB, XP055843287, ISSN: 1754-8403, Retrieved from the Internet <URL:https://journals.biologists.com/Toolbox/DownloadCombinedArticleAndSupplmentPdf?resourceId=3043&multimediaId=1862557&pdfUrl=/cob/content_public/journal/dmm/12/1/10.1242_dmm.035642/6/dmm035642.pdf> DOI: 10.1242/dmm.035642 *
ERCOLANI ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5335 - 15341
GHAREEB ALI E. ET AL: "Coculture techniques for modeling retinal development and disease, and enabling regenerative medicine", STEM CELLS TRANSLATIONAL MEDICINE, vol. 9, no. 12, 1 December 2020 (2020-12-01), US, pages 1531 - 1548, XP055843272, ISSN: 2157-6564, Retrieved from the Internet <URL:https://stemcellsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/sctm.20-0201> DOI: 10.1002/sctm.20-0201 *
HIRAMI ET AL., NEUROSCI. LETT., vol. 48, 2009, pages 126 - 131
HIRAMI ET AL., NEUROSCI. LETT.,, vol. 48, 2009, pages 126 - 131
KARIN ET AL., CELL, vol. 36, 1989, pages 371 - 379
LUDWIG ET AL., NAT. BIOTECHNOL., vol. 24, 2006, pages 185 - 187
LUDWIG ET AL., NAT. METHODS, vol. 3, 2006, pages 637 - 646
MACEJAKSARNOW, NATURE, vol. 353, 1991, pages 90 - 94
NG, NUC. ACID RES., vol. 17, 1989, pages 601 - 615
ONER. TURK J OPHTHALMOL., vol. 48, no. 1, 2018, pages 33 - 8
PELLETIERSONENBERG, NATURE, vol. 334, no. 6180, 1988, pages 320 - 325
PENNINGTONDEANGELIS, EYE VIS (LOND), vol. 3, 2016, pages 34
RICHARDS ET AL., CELL, vol. 37, 1984, pages 263 - 272
SAMBROOKRUSSEL: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LAB. PRESS
SHIMIZU ET AL., CELL GROWTH DIFFER, vol. 8, 1997, pages 1349 - 1358
STRAUSS ET AL., PHYSIOLOGICAL REVIEWS, vol. 85, 2005, pages 845 - 881
STRAUSS, PHYSIOL REV, vol. 85, no. 3, 2005, pages 845 - 81
TAKAHASHI ET AL., CELL, vol. 126, 2006, pages 663 - 676
TAKAHASHI ET AL., CELL, vol. 131, 2007, pages 861 - 872
THOMSON ET AL., PROC. NATL. ACAD. SCIE. USA, vol. 92, 1995, pages 7844 - 7848
THOMSONMARSHALL, CURR. TOP. DEV. BIOL., vol. 38, 1998, pages 133 - 165
THOMSONODORICO, TRENDS BIOTECHNOL., vol. 18, no. 2, 2000, pages 53 - 57
WONG ET AL., THE LANCET GLOBAL HEALTH, vol. 2, no. 2, 2014
YU ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920
ZHAO ET AL., DEVELOPMENT, vol. 144, no. 8, 2017, pages 1368 - 81
ZHOU ET AL., DEVELOPMENT, vol. 142, no. 19, 2015, pages 3294 - 306

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039688A3 (en) * 2022-08-15 2024-04-04 Cellino Biotech, Inc. Systems and methods for cell manufacturing
WO2024157203A1 (en) * 2023-01-27 2024-08-02 Alcon Inc. Induced pluripotent stem cell (ipsc) derived multi-ribbon biodegradable gel for outer retinal replacement
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions
WO2026006245A1 (en) 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Also Published As

Publication number Publication date
US20230212509A1 (en) 2023-07-06
KR20230017876A (ko) 2023-02-06
PH12022553083A1 (en) 2024-03-25
MX2022015002A (es) 2023-03-03
US20260103678A1 (en) 2026-04-16
AU2021280332A1 (en) 2022-12-01
IL298254A (en) 2023-01-01
CN116323677A (zh) 2023-06-23
EP4157865A1 (en) 2023-04-05
CA3180561A1 (en) 2021-12-02
BR112022024064A2 (pt) 2023-01-31
JP2023536210A (ja) 2023-08-24

Similar Documents

Publication Publication Date Title
US12241083B2 (en) Macs-based purification of stem cell-derived retinal pigment epithelium
US20250197802A1 (en) Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
US20250243456A1 (en) Method for differentiation of ocular cells and use thereof
US20260103678A1 (en) Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
US20230201267A1 (en) Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
US20250340836A1 (en) Methods for production of ipscs
HK40096306A (zh) 视网膜色素上皮和光感受器双层及其用途
HK40092893A (zh) 视网膜色素上皮和感光器双细胞聚集物及其使用方法
HK40074568A (en) Macs-based purification of stem cell-derived retinal pigment epithelium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21737240

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202217064350

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2022573582

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3180561

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021280332

Country of ref document: AU

Date of ref document: 20210528

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022024064

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227046209

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021737240

Country of ref document: EP

Effective date: 20230102

ENP Entry into the national phase

Ref document number: 112022024064

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221125